Real-World lupus study reveals how new drug performs outside clinical trials

NCT ID NCT06626945

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 152 adults with systemic lupus erythematosus (SLE) who started taking anifrolumab during its first year on the market in Spain. Researchers tracked their disease activity, flare-ups, and remission rates using standard medical records. The goal was to see how well the drug works in real-world settings, not just in controlled trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Research Site

Barcelona, Spain
Research Site

Granada, Spain
Research Site

Jaén, Spain
Research Site

L'Hospitalet de Llobregat, Spain
Research Site

León, Spain
Research Site

Madrid, Spain
Research Site

Málaga, Spain
Research Site

Mérida, Spain
Research Site

Móstoles, Spain
Research Site

Murcia, Spain
Research Site

Seville, Spain
Research Site

Toledo, Spain
Research Site

Valladolid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.